Patent ID: 8450490

Claim:
A method for treating pulmonary inflammation or bronchoconstriction in a human in need thereof, comprising administering to said human an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: is selected from: wherein R 1 is CH 2 OH, CH 2 CH 2 OH, N(H)C(O)H, N(H)S(O 2 )CH 3 , and R 2 is H: or X is a bicyclic, fused heterocyclic ring selected from the group of: wherein said bicyclic fused heterocyclic ring is optionally substituted with one, two or three additional substituents independently selected from alkyl, oxo, and OH; R 3 is selected from C 4-12 alkylene, C 4-12 alkenylene, C 4-12 alkynylene, R 4 —O—R 4 , R 4 —N(R 8 )—R 4 , C 3-6 cycloalkylene, R 4 —C 3-6 cycloalkylene, C 3-6 cycloalkylene-R 4 , R 4 —C 3-6 cycloalkylene-R 4 , phenylene, R 4 -phenylene, phenylene-R 4 , R 4 -phenylene-R 4 , R 4 -phenylene-O—R 4 , R 4 -phenylene-N(R 8 )—R 4 , R 4 -phenylene-phenylene, Het, R 4 -Het, R 4 -Het-phenylene, Het-R 4 , R 4 -Het-R 4 , R 4 —O-Het R 4 -phenylene-O-Het, R 4 -phenylene-C(O)Het, and R 4 -phenylene-N(R 8 )-Het; wherein said alkylene, alkenylene, alkynylene, cycloalkylene, or arylene is optionally substituted with 1, 2 or 3 substituents selected from halo, oxo, and OR 8 ; Het is 5-6 membered saturated or unsaturated heterocyclene selected from the group of: and wherein said 5-membered or 6-membered saturated or unsaturated heterocyclene is optionally substituted with 1, 2 or 3 substituents selected from halo, alkyl, alkoxy, oxo, and OH; R 4 is C 1-10 alkylene, C 2-10 alkenylene, or C 2-10 alkynylene wherein each R 4 is optionally substituted with 1, 2 or 3 substituents selected from halo, oxo, and OR 8 ; with the proviso that the total number of carbon atoms in the C 1-10 alkylene, C 2-10 alkenylene, or C 2-10 -alkynylene chains of two R 4 groups in any definition of R 3 is not greater than 12; Y is C(O), C(O)N(R 8 )CH 2 , N(R 8 )C(O), O—C(O)N(R 8 )CH 2 , N(R 8 )C(O)N(R 8 )CH 2 , or SO 2 N(R 8 )CH 2 R 5 is alkyl; R 6 is H or alkyl; R 7 is selected from (a) unsubstituted C 3-6 cycloalkyl, (b) C 3-6 cycloalkyl substituted with 1 or 2 substituents selected from halo, alkyl, hydroxyl, —O-alkyl, oxo, amino, alkylamino, dialkylamino, C(O)N 2 , C(O)NHalkyl, and C(O)N(alkyl) 2 , and (c) a heterocyclic group selected from formulas (i), (ii), and (iii): wherein Z is O, S, S(O) 2 , NH or N—R 7a and R 7a is selected from alkyl, C(O)alkyl, C(O)NH 2 , C(O)N(H)alkyl, and C(O)N(alkyl) 2 ; and R 8 is H or alkyl.